{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000150","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.734890+00:00","generated_at":"2026-06-13T10:41:32.675449+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Centessa doses first subject in registrational PRESent-2 study for SerpinPC in hemophilia B","bullets":["Dosed first patient in PRESent-2, a Phase 2b registrational study of SerpinPC for hemophilia B without inhibitors.","Interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of the adaptive design.","SerpinPC is a subcutaneously administered APC inhibitor; potential first-in-class therapy for hemophilia B.","Company expects to start registrational PRESent-3 study for hemophilia B with inhibitors later this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000150","json":"https://secwatch.observer/filing/0001847903-23-000150.json","markdown":"https://secwatch.observer/filing/0001847903-23-000150.md","text":"https://secwatch.observer/filing/0001847903-23-000150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000150/0001847903-23-000150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000150/cnta-20230710.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:41:32.675449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}